Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Credit agrmnt [a]
Gossamer Bio, Inc. (GOSS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 DEL AM Form DEL AM - Delaying amendment:
08/18/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/18/2023 RW Form RW - Registration Withdrawal Request:
08/17/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update - Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 -"
08/07/2023 D Form D - Notice of Exempt Offering of Securities:
07/28/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
07/20/2023 8-K Quarterly results
07/20/2023 8-K Quarterly results
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GOSSAMER BIO, INC."
05/10/2023 SC 13G/A STATE STREET CORP reports a 1.4% stake in EXIT FILING GOSSAMER BIO INC
05/09/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/09/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update - Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study -"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 SC 13G/A BlackRock Inc. reports a 4.9% stake in GOSSAMER BIO, INC.
04/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/03/2023 8-K Other Events  Interactive Data
03/17/2023 10-K Annual Report for the period ended December 31, 2022
03/17/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update - FDA Feedback on Seralutinib Phase 3 Clinical Trial Received&#59; Expected to Commence in the Second Half of 2023 -"
02/14/2023 SC 13G/A HHLR ADVISORS, LTD. reports a 5.3% stake in Gossamer Bio, Inc.
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/10/2023 SC 13G STATE STREET CORP reports a 29.5% stake in INITIAL FILING GOSSAMER BIO INC
01/04/2023 SC 13G MILLENNIUM MANAGEMENT LLC reports a 5.1% stake in GOSSAMER BIO, INC.
12/20/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
12/06/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
08/09/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
07/18/2022 D Form D - Notice of Exempt Offering of Securities:
07/13/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy